Our Pipeline
A clinical-stage company advancing a broad pipeline of novel therapies to address barriers to successful adoptive cell therapy in solid tumors.
We are building a multi-modal pipeline across several indications with high unmet needs for patients with solid tumor cancers.
Lyell has immense potential to target aggressive solid tumor cancers. Our diverse pipeline targets triple-negative breast cancer (TNBC), non small cell lung cancer (NSCLC), melanoma and colorectal cancer (CRC) — but these initial indications are only the beginning. Each of our programs provides opportunities to expand into additional indications beyond the patient populations initially targeted.
Product Candidate/
Modality
Modality
Target
Genetic
Reprogramming
Reprogramming
c-Jun
NR4A3
Epigenetic
Reprogramming
Reprogramming
Epi-R™
Stim-R™
Target Indications
PrePreclinical
Phase 1
Phase 2/
Pivotal
Pivotal
Target
ROR1 is a highly expressed cell surface antigen present on many aggressive solid tumors, including approximately 60% of patients with triple-negative breast cancer (TNBC) and 40% of patients with non-small cell lung cancer (NSCLC).
Target IndicationsBreast cancer is the second most common cancer in American women and approximately 10-15% of patients with breast cancer have TNBC. Lung cancer is the second most common cancer and is the leading cause of cancer mortality worldwide. NSCLC accounts for 84% of all lung cancers.
Development Stage
Phase 1. The Phase 1 open label, dose escalation and expansion clinical trial is designed to evaluate the safety and antitumor activity of LYL797 in patients with ROR1+ TNBC or NSCLC. More information can be found on ClinicalTrials.gov.
Next Milestone
Initial data expected in 1H 2024
Commercial Rights
Target
ROR1 is a highly expressed cell surface antigen present on many aggressive solid tumors.
Development Stage
Preclinical
Next Milestone
IND submission expected in 1H 2024
Commercial Rights
Target: Multiple antigens
Tumor infiltrating lymphocytes (TIL) products are created by expanding T cells taken from the patient’s own tumor. Previous clinical experiences suggest that the efficacy of adoptive transfer of ex vivo expanded TILs is largely driven by specific recognition of mutated tumor neoantigens specific to each patient. To date, broad efficacy of TIL therapies has been limited by variable and often poor product quality, lack of stemness or potential durability of expanded TILs, failure to maintain polyclonality of TILs during production, and failure to enrich the TIL product with tumor-reactive T cells. TIL products manufactured using Lyell’s Epi-R reprogramming technology aim to overcome these challenges.
Target IndicationsInitially targeting melanoma which accounts for only ~1% of all skin cancers but is responsible for ~80% of skin cancer-related deaths. Additional cohorts in the expansion phase of the trial are expected to include patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Development Stage
Phase 1. The Phase 1 clinical trial is an open-label, dose-escalation trial designed to evaluate the safety and anti-tumor activity of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, with expansion cohorts for patients with melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). More information can be found on ClinicalTrials.gov.
Next Milestone
Initial data expected in 2024
Commercial Rights
Learn More About Our Technologies
Our proprietary reprogramming technologies are designed to address barriers to consistent, reliable and durable responses to adoptive cell therapy (ACT) in solid tumors.
Learn More